Photo: Courtesy of Celgene ( Celgene Logo, https://www.celgene.com/media-library/celgene-logo/)
Biopharmaceutical company Celgene has reiterated its stance on the inter partes review (IPR) petitions filed by hedge fund manager Kyle Bass and has hinted it will appeal against a recent unfavourable decision.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Celgene, Patent Trial and Appeal Board, PTAB, USPTO, Coalition for Affordable Drugs, inter partes reviews, patents, Kyle Bass